What is the success rate of Breyanzi?
The success rate of Breyanzi (lisocabtagene maraleucel) varies depending on the condition being treated. Clinical trial data show that complete response rates range from 20% to 73% across different types of lymphoma and leukemia.
Below are clinical trial results for Breyanzi in various conditions, with some patients experiencing partial response to treatment.
Large B-cell lymphoma
Breyanzi was studied in over 250 adults with refractory or relapsed B-cell lymphoma in a multicenter clinical trial. The study showed:
- After treatment with Breyanzi, the complete remission rate was 54%.
- Criteria: 2014 Lugano classification
Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
The complete response rate among patients who took Breyanzi for relapsed or refractory CLL or SLL in a clinical trial called TRANSCEND-CLL was 20%. A total of 65 patients were treated with Breyanzi in the study.
- Criteria: 2018 International Workshop CLL (iwCLL) criteria
Related questions
- What is CAR T-cell therapy and how does it work?
- How will I feel after a Rituxan infusion?
- How long does it take for Rituxan to work?
Follicular lymphoma
In the TRANSCEND-FL clinical trial, adults with relapsed or refractory follicular lymphoma who took Breyanzi had a complete response rate of 73.4%. A total of 94 patients that were treated with Breyanzi were included in the final results. In order to be considered to have complete response, patients who did not have a negative bone marrow biopsy between their most recent disease progression and before starting lymphodepleting chemotherapy were required to have a negative bone marrow biopsy.
Mantle cell lymphoma
Out of 68 patients with relapsed or refractory mantle cell lymphoma who were treated with Breyanzi in the TRANSCEND-MCL trial, 67.6% saw a complete response.
- Criteria: 2014 Lugano classification
Individual responses to Breyanzi vary, and partial responses were also observed in these trials. Speak with your healthcare provider to understand how these results may apply to your specific situation.
References
- Breyanzi [package insert]. Updated June 2025. Juno Therapeutics, Inc. Accessed August 14, 2025 at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=594bb413-af3b-4b97-afb3-bfe2b174f2ed
- U.S. Food and Drug Administration. 2021. FDA Approves New Treatment For Adults With Relapsed Or Refractory Large-B-Cell Lymphoma. Accessed August 6, 2024 at https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-relapsed-or-refractory-large-b-cell-lymphoma
- U.S. Food and Drug Administration. 2024. FDA grants accelerated approval to lisocabtagene maraleucel for follicular lymphoma. Accessed August 6, 2024 at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-lisocabtagene-maraleucel-follicular-lymphoma
- U.S. Food and Drug Administration. 2024. FDA approves lisocabtagene maraleucel for relapsed or refractory mantle cell lymphoma. Accessed August 6, 2024 at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-mantle-cell-lymphoma
Read next
How does the drug Rituxan work?
Rituxan (rituximab) is a monoclonal antibody that targets the CD20 protein found on the surface of B-cells, a type of white blood cell involved in immune responses. By binding to CD20, Rituxan helps eliminate these cells.
Continue reading
What is the difference between Truxima and Rituxan?
Truxima (rituximab-abbs) is a biosimilar to Rituxan (rituximab). While both drugs are CD20-directed cytolytic antibodies used to treat non-Hodgkin’s lymphoma (NHL), Rituxan has additional FDA-approved indications beyond NHL. Continue reading
Is Venclexta (venetoclax) chemotherapy?
Venclexta (venetoclax) is a targeted treatment rather than a type of chemotherapy. Chemotherapy is defined as a drug treatment that kills fast-growing cells in your body. Venclexta works by binding to a specific protein called BCL-2 which is overexpressed on cancerous cells in people with cancers such as AML and CLL. By binding to this protein Venclexta kills cancerous CLL and AML lymphocytes, in preference to other fast-growing cells. Continue reading
See also:
Related medical questions
- What is the success rate of Rituxan (rituximab) in patients with blood cancers?
- How do you prepare for a Rituxan infusion?
- How effective is Venclexta?
- Does Truxima make you gain weight?
- What causes infusion reactions to rituximab?
- How long do you take Venclexta for?
- Does ibrutinib cause hair loss?
- What are the names of the BTK inhibitors?
- Is Truxima a chemotherapy drug?
- How is Bendeka different to Treanda?
- How is Arzerra administered and how long to work?
- What is Arzerra used for and how does it work?
- Is Zydelig a chemotherapy drug?
- What is Zydelig used for and how does it work?
- What is the difference between Rituxan and Rituxan Hycela?
- Who makes Leukeran, and where is it made?
- How is Rituxan Hycela administered?
- How does Venclexta work?
- How long does it take for Jaypirca to work?
- How to apply for and use the Imbruvica copay card?
- What type of drug is Copiktra?
- What is the cost of Kymriah?
- What is the cost of Yescarta?
- What's the difference between Kymriah and Yescarta?
- How does Monjuvi work?
- How is Monjuvi given / administered?
- What is the success rate of Epkinly?
- What is the survival rate of Kymriah?
- How is Kymriah administered?
- How is Yescarta administered?
Drug information
- Breyanzi Information for Consumers
- Breyanzi prescribing info & package insert (for Health Professionals)
- Side Effects of Breyanzi (detailed)
Related support groups
- Breyanzi (2 questions, 3 members)
- Chronic Lymphocytic Leukemia (CLL) (27 questions, 57 members)
- Follicular Lymphoma (21 questions, 15 members)
- Diffuse Large B-Cell Lymphoma (19 questions, 3 members)
- B Cell Lymphoma (10 questions, 3 members)
- Mantle Cell Lymphoma (10 questions, 9 members)